Ti-mesh

PreclinicalBiologic

TTufts University

Ti-mesh is one of 5 biologic programs targeting Morbidity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MorbidityActive, not recruiting

MorbidityPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Morbidity

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 2

1 2

Minipress

Pfizer

Preclinical

1 3

Luvox

SSolvay Pharmaceuticals

Preclinical

1 4

Ti-mesh

TTufts University

Preclinical

1 5

Psychotropic Drugs

UUniversity of Washington

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Morbidity1 trial

Comparing the Efficacy and Morbidity of Two Vertical Ridge Augmentation Techniques

Active, not recruiting·TTufts University·N/A·NCT02703480·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ti-mesh. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ti-mesh compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ti-mesh. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tufts University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: TTufts University

Ti-mesh

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Morbidity1 trial

References

Drug Info

Quick Facts

Related News